Literature DB >> 19805525

A heterologous helper T-cell epitope enhances the immunogenicity of a multiple-antigenic-peptide vaccine targeting the cryptic loop-neutralizing determinant of Bacillus anthracis protective antigen.

Jon Oscherwitz1, Fen Yu, Kemp B Cease.   

Abstract

We previously showed that a multiple antigenic peptide (MAP) displaying amino acids (aa) 305 to 319 from the 2beta2-2beta3 loop of protective antigen (PA) can elicit high-titered antibody that neutralizes lethal toxin (LeTx) in vitro and that this loop-neutralizing determinant (LND) specificity is absent in PA-immune rabbits. Some immune rabbits were, however, nonresponders to the MAP. We hypothesized that the immunogen elicited suboptimal major histocompatibility complex (MHC) class II-restricted T-cell help and that introduction of a functional helper T-cell epitope would increase MHC-restricted responsiveness and the magnitude and affinity of the antibody responses. In the current study, we characterized the T- and B-cell responses to LND peptides in mice, then designed second-generation MAP immunogens for eliciting LND-specific immunity, and tested them in rabbits. The 305-319 sequence was devoid of helper T-cell epitopes in three strains of mice; however, a T-B peptide comprising aa 305 to 319, colinearly synthesized with the P30 helper epitope of tetanus toxin, elicited robust LeTx-neutralizing immunity in mice. T-B MAPs displaying B-cell epitopes 304 to 319 (MAP304) or 305 to 319 (MAP305) elicited high-titer, durable antibody responses in rabbits which exhibited potent neutralization of LeTx in vitro. All MAP304-immune rabbits demonstrated neutralization titers exceeding that of hyperimmune sera of rabbits immunized with PA in Freund's adjuvant, with peak neutralization titers 23-, 6-, and 3-fold higher than that of the PA antiserum. Overall, immunization with MAPs containing the P30 epitope elicited higher antibody and toxin neutralization titers and peptide-specific affinity than immunization with an LND MAP lacking a helper epitope. P30-containing MAP304 represents a promising LND-specific vaccine for anthrax.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19805525      PMCID: PMC2786483          DOI: 10.1128/IAI.00899-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  50 in total

1.  Proteins and their derived peptides as carriers in a conjugate vaccine for Streptococcus pneumoniae: self-heat shock protein 60 and tetanus toxoid.

Authors:  Hila Amir-Kroll; Gabriel Nussbaum; Irun R Cohen
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

2.  Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.

Authors:  C Y Wang; D J Looney; M L Li; A M Walfield; J Ye; B Hosein; J P Tam; F Wong-Staal
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

3.  Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.

Authors:  S F Little; B E Ivins; W M Webster; P F Fellows; M L M Pitt; S L W Norris; G P Andrews
Journal:  Vaccine       Date:  2005-12-27       Impact factor: 3.641

4.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

6.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Authors:  Stephen F Little; Jeanne M Novak; John R Lowe; Stephen H Leppla; Yogendra Singh; Kurt R Klimpel; Burton C Lidgerding; Arthur M Friedlander
Journal:  Microbiology (Reading)       Date:  1996-03       Impact factor: 2.777

7.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

8.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

9.  Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Pickard; G Allen; R O Thomson
Journal:  J Bacteriol       Date:  1986-01       Impact factor: 3.490

10.  Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Michael J Gubbins; Jody D Berry; Cindi R Corbett; Jeremy Mogridge; Xin Y Yuan; Lisa Schmidt; Brigitte Nicolas; Amin Kabani; Raymond S Tsang
Journal:  FEMS Immunol Med Microbiol       Date:  2006-08
View more
  10 in total

1.  An epitope of Bacillus anthracis protective antigen that is cryptic in rabbits may be immunodominant in humans.

Authors:  Rebecca J Ingram; Karen K Chu; Gökhan Metan; Bernard Maillere; Mehmet Doganay; Yusuf Ozkul; Hugh Dyson; E Diane Williamson; Les Baillie; Louise U Kim; Stephanie Ascough; Shiranee Sriskandan; Daniel M Altmann
Journal:  Infect Immun       Date:  2010-05       Impact factor: 3.441

Review 2.  Lost in translation--basic science in the era of translational research.

Authors:  Ferric C Fang; Arturo Casadevall
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

3.  The promise and challenge of epitope-focused vaccines.

Authors:  Jon Oscherwitz
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

4.  Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Daniel Feldman; Fen Yu; Kemp B Cease
Journal:  Vaccine       Date:  2014-11-30       Impact factor: 3.641

5.  Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.

Authors:  Jon Oscherwitz; Conrad P Quinn; Kemp B Cease
Journal:  Vaccine       Date:  2015-03-26       Impact factor: 3.641

6.  Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Kemp B Cease
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

7.  Location of immunization and interferon-γ are central to induction of salivary gland dysfunction in Ro60 peptide immunized model of Sjögren's syndrome.

Authors:  Hongen Yin; Jelle L Vosters; Nienke Roescher; Anil D'Souza; Biji T Kurien; Paul P Tak; John A Chiorini
Journal:  PLoS One       Date:  2011-03-28       Impact factor: 3.240

8.  Identification and validation of a linear protective neutralizing epitope in the β-pore domain of alpha toxin.

Authors:  Jon Oscherwitz; Kemp B Cease
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

9.  Calcium Phosphate Nanoparticle-Based Vaccines as a Platform for Improvement of HIV-1 Env Antibody Responses by Intrastructural Help.

Authors:  Dominik Damm; Leonardo Rojas-Sánchez; Hannah Theobald; Viktoriya Sokolova; Richard T Wyatt; Klaus Überla; Matthias Epple; Vladimir Temchura
Journal:  Nanomaterials (Basel)       Date:  2019-09-27       Impact factor: 5.076

10.  Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.

Authors:  Vladimir Temchura; Klaus Überla; Hassan Elsayed; Ghulam Nabi; William J McKinstry; Keith K Khoo; Johnson Mak; Andres M Salazar; Matthias Tenbusch
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.